Advertisement
Document › Details
Adrenomed AG. (8/13/19). "Press Release: Adrenomed AG Takes Part in Four Upcoming Conferences". Hennigsdorf.
Organisation | Adrenomed AG | |
Organisation 2 | University of Nijmegen (Radboud University) | |
Product | Adrecizumab | |
Product 2 | Sachs Annual Biotech in Europe Forum 2019 Basel | |
Person | Hein, Frauke (Bico 202206– CEO of Scienion before MLDx GmbH + Adrenomed + BRAHMS + Brandenburg) | |
Person 2 | von Hummel, Julia (MC Services 201811) | |
Adrenomed AG, the vascular integrity company, announced today its participation at four upcoming conferences in Europe. Adrenomed representatives will be available for networking and one-to-one meetings at the following events:
Weimar Sepsis Update – Symposium
September 11th – 13th, 2019, Congress Centrum Neue Weimarhalle, Weimar, Germany
Adrenomed will co-host the lunch symposium “Beyond Standard of Care – New Perspectives on Vascular Integrity in Shock” on September 13th, 12:00 – 13:30 CET.
https://www.sepsis-gesellschaft.de/kongress/
19th Annual Biotech in Europe Forum (Sachs Conference)
September 25th – 26th, 2019, Congress Center Basel, Switzerland
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will participate in the “Platform Technologies & Novel Therapeutics Panel” on September 25th, 10:45 CET.
https://www.sachsforum.com/bef19-about.html
European Business Development Conference (EBDC)
September 25th – 26th, 2019, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will give a “Spotlight Talk on Sepsis” on September 26th, 12:00 CET.
https://www.biodeutschland.org/de/european-business-development-conference-2019.html
32nd European Society of Intensive Care Medicine (ESICM) LIVES
September 28th – October 2nd, 2019, CityCube, Berlin, Germany
Prof. Dr. Peter Pickkers, Radboud University, Department of Intensive Care, Nijmegen, The Netherlands, will give a presentation about “Adrenomedullin in sepsis, effect of the non-inhibitory antibody Adrecizumab”, session “Innovation in sepsis treatment”, on October 1st, 16:20 CET, room Stockholm.
https://www.esicm.org/events/32nd-annual-congress-berlin/
About Adrenomed
Adrenomed AG is a German privately-financed, clinical stage biopharmaceutical company. Adrenomed´s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company’s lead product candidate Adrecizumab is a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials. www.adrenomed.com
Adrenomed AG
@adrenomed
Contact
Adrenomed AG
Frauke Hein, Ph.D. (Chief Business Officer)
phone: +49 (0)3302 2077814
fhein@adrenomed.com
Media Inquiries
MC Services AG
Eva Bauer/Julia von Hummel
phone: +49 (0)89 21022880
adrenomed@mc-services.eu
Record changed: 2023-06-05 |
Advertisement
More documents for Adrenomed AG
- [1] InfanDx AG. (9/1/22). "Press Release: InfanDx AG Appoints Nicole Witzmann as Chief Financial Officer". Cologne, Berlin & Boston, MA....
- [2] Scienion GmbH. (6/1/22). "Press Release: Scienion Appoints Frauke Hein as CEO". Berlin....
- [3] Adrenomed AG. (1/4/21). "Press Release: Adrenomed Supervisory Board Appoints Dr. Wolfgang Baiker as CEO". Hennigsdorf....
- [4] Adrenomed AG. (5/6/19). "Press Release: Adrenomed AG Takes Part in Three Upcoming Conferences". Hennigsdorf....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top